James Xue
Chairman, President and CEO
Professional Overview
James Xue is an accomplished life sciences executive with over 20 years of experience in the biopharmaceutical and rare disease industries. As the Chairman, President and CEO of CANbridge Pharmaceuticals Inc., he provides strategic leadership and drives the company's mission to develop innovative treatments for rare and ultra-rare diseases. Additionally, Xue serves in key advisory roles with the Shanghai Foundation for Rare Disease and the China Alliance for Rare Disease (CHARD), leveraging his deep expertise to shape the rare disease landscape in China.
Experience Summary
Current Roles
Chairman, President and CEO, CANbridge Pharmaceuticals Inc. (2012-Present)
- Provides executive leadership and vision to guide CANbridge's growth as a leading rare disease-focused biopharmaceutical company
- Oversees the company's strategic direction, pipeline development, and commercialization efforts, advancing multiple rare disease therapies through clinical trials
- Drives strategic partnerships and collaborations to expand CANbridge's global reach and impact
Deputy Director General, Shanghai Foundation for Rare Disease (2019-Present)
- Advises the foundation on strategic initiatives and programs to support rare disease patients and their families in China
- Leverages industry expertise to shape policy and healthcare initiatives that improve access to rare disease treatments
Deputy Director General, China Alliance for Rare Disease (CHARD) (2018-Present)
- Contributes to the alliance's efforts to establish a comprehensive rare disease ecosystem in China, including research, patient advocacy, and policy development
Career Progression
Xue's career in the life sciences industry spans various leadership roles, with a strong focus on rare diseases and the Chinese market. Prior to founding CANbridge, he held positions at Genzyme Corporation, where he led the company's China operations and spearheaded market development and commercial strategy. Xue also gained experience in business development and scientific research, working at Kosan Biosciences and serving as a venture partner at Tullis Health Investors.
Academic Background
Xue holds a Bachelor of Science degree in Biochemistry from Fudan University in Shanghai, China.
Areas of Expertise
- Rare disease drug development and commercialization
- Biopharmaceutical strategy and operations
- Rare disease policy and advocacy
- Navigating the Chinese healthcare landscape
- Collaborative leadership and stakeholder engagement
Professional Impact
Under Xue's leadership, CANbridge has established itself as a leading rare disease-focused biopharmaceutical company in China, with a diverse pipeline of promising therapies. His contributions to the Shanghai Foundation for Rare Disease and CHARD have been instrumental in advancing the rare disease agenda in China, driving initiatives that improve patient access and care.
Conclusion
James Xue's extensive experience, industry expertise, and strategic vision have positioned him as a prominent figure in the rare disease space, both in China and globally. As he continues to lead CANbridge and shape rare disease initiatives, Xue remains dedicated to improving the lives of patients and their families through the development of innovative treatments and the advancement of rare disease healthcare policies.
